VIM and cancer: Compared with placebo control, bosentan treatment did not significantly change the mRNA levels of Cyclin D1, MMP2, Vimentin and ETB under conditions of fibrocyte depletion, except leading to a slight downregulation of mRNA expression of ETA in cancer cells (Fig. 10E).